Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
3(75.0%)
Phase 2
1(25.0%)
4Total
Phase 1(3)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT04731051Phase 1Withdrawn

The Potential Use of Inhaled Hydroxychloroquine for the Treatment of COVID-19 in Cancer Patients

Role: collaborator

NCT05663372Phase 1Completed

Bioequivalence Study of Test and Reference 50 mg Eplerenone Film-coated Tablets in Healthy Volunteers

Role: collaborator

NCT05663398Phase 1Completed

Bioequivalence Study of Test and Reference 400 mg Ibuprofen Coated Tablets in Healthy Volunteers

Role: collaborator

NCT05113810Phase 2Unknown

The Potential Use of Nebulized Hydroxychloroquine for the Treatment of COVID-19

Role: collaborator

All 4 trials loaded